PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy
PQR309 是一种新型双重 PI3K/mTOR 抑制剂,作为单一药物和联合疗法在淋巴瘤中具有临床前抗肿瘤活性
期刊:Clinical Cancer Research
影响因子:10
doi:10.1158/1078-0432.CCR-17-1041
Chiara Tarantelli #, Eugenio Gaudio #, Alberto J Arribas, Ivo Kwee, Petra Hillmann, Andrea Rinaldi, Luciano Cascione, Filippo Spriano, Elena Bernasconi, Francesca Guidetti, Laura Carrassa, Roberta Bordone Pittau, Florent Beaufils, Reto Ritschard, Denise Rageot, Alexander Sele, Barbara Dossena, Franc